Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 15/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7673285 | 0.99 | CCR5 (0.36) | CCR5LMNACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7674864 | 0.64 | LMNA (0.43) | LMNACYP3A4CYP2D6MAPTMAPK1 | |
| SCHEMBL7170492 | 0.62 | ALDH1A1 (0.46) | LMNAMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL7669155 | 0.62 | LMNA (0.37) | LMNAMAPTMAPK1KMT2A | |
| SCHEMBL17676992 | 0.58 | KDM4E (0.59) | LMNAMAPTMAPK1KMT2ATP53 | |
| SCHEMBL10326483 | 0.58 | KDM4E (0.59) | LMNAMAPTMAPK1KMT2ATP53 | |
| SCHEMBL10327021 | 0.58 | KDM4E (0.59) | LMNAMAPTMAPK1KMT2ATP53 | |
| SCHEMBL3124456 | 0.55 | GAA (0.51) | — | |
| SCHEMBL17867151 | 0.55 | GAA (0.51) | — | |
| SCHEMBL2864427 | 0.55 | GAA (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0657166-B1 | Combination containing a quinoxaline and a nucleoside | AVENTIS PHARMA GMBH (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-6369057-B1 | VIRICIDES, IN PARTICULAR AGAINST RETROVIRUSES, HUMAN IMMUNODEFICIENCY VIRUS (HIV) | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| EP-0509398-B1 | Quinoxalines, process for their preparation and their use | AVENTIS PHARMA GMBH (DE) | 2001-09-19 | — | — | EP | disclosed |
| EP-0657166-A1 | Combination containing a quinoxaline and a nucleoside | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0509398-A1 | Quinoxalines, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-10-21 | — | — | EP | disclosed |